| Literature DB >> 22634834 |
Suvitha Syam1, Siddig Ibrahim Abdelwahab, Mohammed Ali Al-Mamary, Syam Mohan.
Abstract
Several chalcones were synthesized and their in vitro cytotoxicity against various human cell lines, including human breast adenocarcinoma cell line MCF-7, human lung adenocarcinoma cell line A549, human prostate cancer cell line PC3, human adenocarcinoma cell line HT-29 (colorectal cancer) and human normal liver cell line WRL-68 was evaluated. Most of the compounds being active cytotoxic agents, four of them with minimal IC₅₀ values were chosen and studied in detail with MCF-7 cells. The compounds 1, 5, 23, and 25 were capable in eliciting apoptosis in MCF-7 cells as shown by multiparameter cytotoxicity assay and caspase-3/7, -8, and -9 activities (p < 0.05). The ROS level showed 1.3-fold increase (p < 0.05) at the low concentrations used and thus it was concluded that the compounds increased the ROS level eventually leading to apoptosis in MCF-7 cells through intrinsic as well as extrinsic pathways.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22634834 PMCID: PMC6268294 DOI: 10.3390/molecules17066179
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of different chalcones synthesized in this study. ‘Cpd’ stands for an abbreviation of “Compound”.
Chemical data for compounds 1–25.
| No | Reactants | Chalcone (Chemical name) | Formula |
|---|---|---|---|
| 1 | Acetophenone + Benzaldehyde | 1,3-Diphenylpropenone | C15H12O |
| 2 | 4H Acetophenone + Benzaldehyde | 1-(4-Hydroxyphenyl)-3-phenylpropenone | C15H12O2 |
| 3 | 4-Methylacetophenone + Benzaldehyde | 3-Phenyl-1-
| C16H14O |
| 4 | 4-Methoxyacetophenone + Benzaldehyde | 1-(4-Methoxyphenyl)-3-phenylpropenone | C16H14O2 |
| 5 | Acetophenone + 2-Chloro-benzaldehyde | 3-(2-Chlorophenyl)-1-phenylpropenone | C15H11OCl |
| 6 | 4H Acetophenone + 2-Chloro-benzaldehyde | 3-(2-Chlorophenyl)-(4-hydroxyphenyl)-propenone | C15H11O2Cl |
| 7 | 4-Methylacetophenone + 2-Chloro-benzaldehyde | 3-(2-Chlorophenyl)-1-P-tolylpropenone | C16H13OCl |
| 8 | 4-Methoxyacetophenone + 2-Chloro-benzaldehyde | 3-(2-Chlorophenyl)-1-(4-methoxy-phenyl)propenone | C16H13O2Cl |
| 9 | Acetophenone + 3-Methyl-benzaldehyde | 1-Phenyl-3-
| C16H14O |
| 10 | 4H Acetophenone + 3-Methyl-benzaldehyde | 1-(4-Hydroxyphenyl)-3-
| C16H14O2 |
| 11 | 4-Methylacetophenone + 3-Methyl-benzaldehyde | 3-
| C17H16O |
| 12 | 4-Methoxyacetophenone + 3-Methyl-benzaldehyde | 1-(4-Methoxyphenyl)-3-
| C17H16O2 |
| 13 | Acetophenone + Anisaldehyde | 3-(4-Methoxyphenyl)-1-phenylpropenone | C16H14O2 |
| 14 | 4H Acetophenone + Anisaldehyde | 1-(4-Hydroxyphenyl)-3-(4-methoxyphenyl)-propenone | C16H15O3 |
| 15 | 4-Methylacetophenone + Anisaldehyde | 3-(4-Methoxyphenyl)-1-
| C17H16O2 |
| 16 | 4-Methoxyacetophenone + Anisaldehyde | 1,3-Bis-(4-Methoxyphenyl)-propenone | C17H16O3 |
| 17 | Acetophenone + 4-Dimethylamino- benzaldehyde | 3-(4-Dimethylaminophenyl)-1-phenyl-propenone | C17H17NO |
| 18 | 4H Acetophenone + 4-Dimethylamino-benzaldehyde | 3-(4-Dimethylaminophenyl)-1-(4-hydroxy-phenyl)-propenone | C17H17NO2 |
| 19 | 4-Methylacetophenone + 4-Dimethylamino- benzaldehyde | 3-(4-Dimethylaminophenyl)-1-
| C18H19NO |
| 20 | 4-Methoxyacetophenone + 4-Dimethylamino-benzaldehyde | 3-(4-Dimethylaminophenyl)-1-(4-methoxy-phenyl)-propenone | C18H19NO2 |
| 21 | Acetophenone + Salicylaldehyde | 3-(2-Hydroxyphenyl)-1-phenylpropenone | C15H12O2 |
| 22 | 4H Acetophenone + Salicylaldehyde | 3-(2-Hydroxyphenyl)-1-(4-hydroxyphenyl)-propenone | C15H12O3 |
| 23 | 4-Methylacetophenone + Salicylaldehyde | 3-(2-Hydroxyphenyl)-1-
| C16H14O2 |
| 24 | 4-Methoxyacetophenone + Salicylaldehyde | 3-(2-Hydroxyphenyl)-1-(4-methoxyphenyl)-propenone | C16H14O3 |
| 25 | Acetophenone + 3-Chlorobenzaldehyde | 3-(3-Chlorophenyl)-1-phenylpropenone | C15H11OCl |
Spectral data, yield and melting point of compounds 1–25.
| Cpd. | IR-Spectrum (KBr), сm−1 | 1H-NMR spectrum (δ, ppm) | Yield (%) | m.p. (°C) |
|---|---|---|---|---|
| 1 | 3030 (C-H aromatic), 1664 (C=O), 1598 (C=C) | 7.77 (d, 1Hα), 8.08 (d, 1Hβ), 7.4–8 (m, 10H, Ar-H) | 70–80 | 56–57 |
| 2 | 3083 (C-H aromatic), 1680 (C=O), 1580 (C=C), 3380 (-OH) | 7.56 (d, 1Hα), 7.99 (d, 1Hβ), 7.04–7.9 (m, 9H, Ar-H), 12.9 (s, 1H, -OH) | 35–45 | 120–121 |
| 3 | 3030 (C-H aromatic), 1649 (C=O), 1598 (C=C) | 7.38 (d, 1Hα), 8.1 (d, 1Hβ), 7.5–7.9 (m, 9H, Ar-H), 2.29 (s, 3H, -CH3) | 70–73 | 70–72 |
| 4 | 3047 (C-H aromatic), 1649 (C=O), 1603 (C=C), 1128 (-OCH3) | 7.19 (d, 1Hα), 8.2 (d, 1Hβ), 7.29–7.9 (m, 9H, Ar-H), 3.79 (s, 3H, -OCH3) | 70–74 | 108–110 |
| 5 | 3047 (C-H aromatic), 1664 (C=O), 1608(C=C), 829 (Ar-Cl) | 7.9 (d,1Hα), 8.2 (d, 1Hβ), 7.39–8 (m, 9H, Ar-H) | 75–80 | 53–54 |
| 6 | 3452 (-OH), 1690 (C=O), 1613 (C=C), 829 (Ar-Cl) | 7.5 (d, 1Hα), 8.19 (d, 1Hβ), 6.4–8 (m, 8H, Ar-H), 12.7 (s, 1H, -OH) | 40–43 | 191–193 |
| 7 | 3052 (C-H aromatic), 1664 (C=O), 1598 (C=C), 829 (Ar-Cl) | 7.9 (d, 1Hα), 8.19 (d, 1Hβ), 7.3–8.1 (m, 8H, Ar-H), 2.3 (s, 3H, -CH3) | 70–75 | 50–51 |
| 8 | 3034 (C-H aromatic), 1664 (C=O), 1590 (C=C), 1130 (-OCH3), 828 (Ar-Cl) | 7 (d, 1Hα), 7.7 (d, 1Hβ), 6.9–8.1 (m, 8H, Ar-H), 3.79 (s, 3H, -OCH3) | 60–65 | 124–126 |
| 9 | 3057 (C-H aromatic), 1664 (C=O), 1590 (C=C) | 7.19 (d,1Hα), 8.2 (d, 1Hβ), 7.2–8 (m, 9H, Ar-H), 2.3 (s, 3H, -CH3) | 68–70 | 68–70 |
| 10 | 3457 (-OH), 3011 (C-H aromatic), 1685 (C=O), 1591 (C=C) | 7.2 (d, 1Hα), 7.7 (d, 1Hβ), 7.1–8 (m, 8H, Ar-H), 12.8 (s, 1H, -OH), 2.3 (s, 3H, CH3) | 30 | 114–116 |
| 11 | 3027 (C-H aromatic), 1654 (C=O), 1593 (C=C) | 7.8 (d, 1Hα), 8.2 (d, 1Hβ), 7.1–8 (m, 8H, Ar-H), 2.3 (s, 3H, -CH3) | 84 | 89–91 |
| 12 | 3011 (C-H aromatic), 1659 (C=O), 1588 (C=C), 1126 (-OCH3) | 7.19 (d, 1Hα), 8.21 (d, 1Hβ), 6.9–8 (m, 8H, Ar-H), 3.8 (s, 3H, -OCH3), 2.96 (s, 3H, CH3) | 80 | 74–75 |
| 13 | 3057 (C-H aromatic), 1659 (C=O), 1588 (C=C), 1168 (-OCH3) | 7 (d, 1Hα), 8.2 (d, 1Hβ), 6.9–8.2 (m, 9H, Ar-H), 3.8 (s, 3H, -OCH3) | 80 | 77–78 |
| 14 | 3380 (-OH), 3035 (C-H aromatic) 1660 (C=O), 1590 (C=C), 1166 (-OCH3) | 6.9 (d, 1Hα), 7.9 (d, 1Hβ), 6.7–8.1 (m, 8H, Ar-H), 12.8 (s, 1H, -OH), 3.8 (s, 3H, -OCH3) | 35 | 179–181 |
| 15 | 3080 (C-H aromatic), 1649 (C=O), 1588 (C=C), 1170 (-OCH3) | 7.7 (d, 1Hα), 8.2 (d, 1Hβ), 6.9–8.2 (m, 8H, Ar-H), 2.29 (s, 3H, -CH3), 3.8 (s, 3H, -OCH3) | 85–90 | 99–100 |
| 16 | 3033 (C-H aromatic), 1659 (C=O), 1588 (C=C), 1168 (-OCH3) | 7.7 (d, 1Hα), 8.2 (d, 1Hβ), 6.9–8.2 (m, 8H, Ar-H), 3.8(s, 3H, -OCH3), 3.8 (s, 3H, OCH3) | 80–88 | 102–103 |
| 17 | 3010 (C-H aromatic), 1654(C=O), 1562(C=C), 1340 (C-N) | 6.7 (d, 1Hα), 8.21 (d, 1Hβ), 7.3–7.8 (m, 9H, Ar-H), 2.9 (s, 6H, N-(CH3)2) | 80 | 111–113 |
| 18 | 3380 (-OH), 3012 (C-H aromatic), 1664 (C=O), 1598 (C=C), 1372 (C-N) | 6.8 (d, 1Hα), 8.7 (d, 1Hβ), 6.8–8.8 (m, 8H, Ar-H), 9.7 (s, 1H, -OH), 2.99 (s, 6H, N-(CH3)2) | 47 | 76–78 |
| 19 | 3083 (C-H aromatic), 1649 (C=O), 1603 (C=C), 1360 (C-N) | 6.7 (d, 1Hα), 8.21 (d, 1Hβ), 7.3–8 (m, 8H, Ar-H), 2.98 (s, 6H, N-(CH3)2), 2.3 (s, 3H, -CH3) | 70 | 124–125 |
| 20 | 3010 (C-H aromatic), 1650 (C=O), 1593 (C=C), 1161 (-OCH3), 1330 (C-N) | 6.7 (d, 1Hα), 8.2 (d, 1Hβ), 6.7–8.1 (m, 8H, Ar-H), 2.9 (s, 6H, N-(CH3)2), 3.79 (s, 3H, -OCH3) | 86–90 | 129–131 |
| 21 | 1639 (C=O), 1557 (C=C), 3206 (-OH), 3010 (C-H aromatic) | 7.6 (d, 1Hα), 8.2 (d, 1Hβ), 6.7–8.2 (m, 9H, Ar-H), 10.3 (s, 1H, -OH) | 50 | 154–155 |
| 22 | 1669 (C=O), 1590 (C=C), 3467 (-OH), 3005 (C-H aromatic) | 7.8 (d, 1Hα), 7.5 (d, 1Hβ), 6.3–8.3 (m, 8H, Ar-H), 10.2 (s, 1H, -OH), 10.2 (s, 1H, -OH) | 8–10 | 287–289 |
| 23 | 1644 (C=O), 1577 (C=C) , 3216 (-OH), 3030 (C-H aromatic) | 6.8 (d, 1Hα), 7.8 (d, 1Hβ), 6.7–8.2 (m, 8H, Ar-H), 10.2 (s, 1H, -OH), 2.28 (s, 3H, -CH3) | 37–40 | 165–167 |
| 24 | 3252 (-OH), 3000 (C-H aromatic), 1640 (C=O), 1603 (C=C), 1165 (-OCH3) | 7.96 (d, 1Hα), 8.19 (d, 1Hβ), 6.7–8.2 (m, 8H, Ar-H), 10.19 (s, 1H, -OH), 3.69 (s, 3H, OCH3) | 45 | 151–153 |
| 25 | 1654 (C=O), 1603 (C=C), 3052 (C-H aromatic), 823 (Ar-Cl) | 7.9 (d, 1Hα), 8.2 (d, 1Hβ), 7.2–8 (m, 9H, Ar-H) | 80 | 78–80 |
Cytotoxicity of compounds on different cell lines.
| Compound | Cell lines/IC50 values (µg/mL) | ||||
|---|---|---|---|---|---|
| A549 | PC3 | MCF-7 | HT-29 | WRL68 | |
| 1 | 16.76 ± 1.08 | 9.108 ± 0.9 | 6.875 ± 0.219 | 10.1 ± 1.01 | 10.55 ± 0.89 |
| 2 | >100 | >100 | >100 | >100 | >100 |
| 3 | 36.58 ± 1.76 | 17.30 ± 1.1 | 13.62 ± 1.01 | 19.10 ± 1.00 | 21.34 ± 3.01 |
| 4 | 77.04 ± 2.1 | 21.13 ± 1.24 | 19.15 ± 1.0 | 37.28 ± 2.81 | 57.29 ± 3.8 |
| 5 | 19.94 ± 1.66 | 13.84 ± 1.2 | 7.992 ± 0.81 | 13.24 ± 1.2 | 11.46 ± 1.1 |
| 6 | 25.22 ± 1.21 | 10.99 ± 1.8 | 10.01 ± 1.4 | 15.52 ± | 13.22 ± 1.3 |
| 7 | >100 | >100 | >100 | >100 | >100 |
| 8 | >100 | >100 | >100 | >100 | >100 |
| 9 | 24.74 ± 2.0 | 9.40 ± 1.9 | 9.34 ± 0.56 | 18.96 ± 1.5 | 9.78 ± 1.01 |
| 10 | 19.68 ± 1.22 | 13.71 ±1.1 | 8.343 ± 0.472 | 12.1 ± 3.0 | 13.45 ± 2.09 |
| 11 | 24.89 ± 1.9 | 8.73 ± 0.21 | 10.16 ± 1.89 | 16.30 ± 1.9 | 13.95 ± 1.3 |
| 12 | 31.76 ± 1.5 | 9.87 ± 0.71 | 9.53 ± 1.99 | 15.76 ± 2.1 | 11.13 ± 1.8 |
| 13 | 32.57 ± 2.5 | 12.09 ± 0.99 | 11.62 ± 0.101 | 22.79 ± 2.3 | 21.46 ± 1.7 |
| 14 | >100 | >100 | >100 | >100 | >100 |
| 15 | >100 | 43.27 ± 4.01 | 32.37 ± 1.88 | 29.55 ± 2.8 | 50.94 ± 3.51 |
| 16 | >100 | >100 | 41.44 ± 1.91 | 67.07 ± 4.1 | 60.79 ± 4.22 |
| 17 | >100 | >100 | 99.29 ± 6.16 | 64.26 ± 5.02 | >100 |
| 18 | >100 | >100 | >100 | >100 | >100 |
| 19 | 58.54 ± 3.2 | >100 | 57.28 ± 3.1 | 69.54 ± 4.23 | 39.78 ± 3.9 |
| 20 | 78.85 ± 4.4 | >100 | >100 | >100 | >100 |
| 21 | 22.61 ± 1.1 | 11.07 ± 0.4 | 9.353 ± 1.2 | 19.84 ± 2.01 | 17.02 ± 1.7 |
| 22 | >100 | >100 | >100 | >100 | >100 |
| 23 | 16.79 ± 1.76 | 9.492 ± 0.7 | 6.873 ± 1.2 | 12.98 ± 0.54 | 9.533 ± 1.5 |
| 24 | 14.16 ± 1.0 | 5.584 ± 0.2 | 7.149 ± 0.4 | 11.43 ± 1.0 | 8.722 ± 1.0 |
| 25 | 14.49 ± 0.2 | 6.936 ± 0.61 | 5.251 ± 0.67 | 7.772 ± 1.1 | 7.72 ± 1.6 |
Figure 2Representative images of MCF7 cells treated with medium alone and compounds, and stained with nuclear staining dye, cell permeability dye, mitochondrial membrane potential dye and cytochrome c. The images from each row are obtained from the same field of the same treatment sample. MCF7 cells produced a marked reduction in mitochondrial membrane potential, and marked increases in membrane permeability and cytochrome c. (Magnification 20X). (1A- 3 µg/mL; 1B- 6 µg/mL), (23A- 3 µg/mL; 23B- 6 µg/mL), (25A- 2 µg/mL; 25B- 4 µg/mL) and (5A- 3 µg/mL; 5B- 6 µg/mL). The positive control used in the analysis was tamoxifen (0.04 µg/mL). “Cpd” refers to compound.
Figure 3Quantitative analysis of compounds mediated apoptosis parameter. Changes in (A) total nuclear intensity; (B) cell permeability; (C) mitochondrial membrane potential and (D) cytochrome c localization were all measured simultaneously in MCF7 cells. Following treatment with compounds 1, 23, 25 and 5, there was statistically significant cell loss (data not shown), increased total nuclear intensity, increased cell permeability, loss of mitochondrial membrane potential and cytochrome c release from mitochondria with good p values. (1A- 3 µg/mL; 1B- 6 µg/mL), (23A- 3 µg/mL; 23B- 6 µg/mL), (25A- 2 µg/mL; 25B- 4 µg/mL) and (5A- 3 µg/mL; 5B- 6 µg/mL). The positive control used in the analysis was tamoxifen (0.04 µg/mL). Each experiment was performed at least two times. Results are expressed as the means value ± standard deviation (SD). Statistical analysis was performed with one-way analysis of variance (ANOVA) using GraphPad Prism software (version 4.0; GraphPad Software Inc.). Statistical significance is expressed as *, p < 0.05.
Figure 5Fold increase of reactive oxygen species (ROS) in MCF-7 cells after treatment with compounds 1, 23, 25, and 5 compared to control (untreated MCF-7 cells). (1A- 3 µg/mL; 1B- 6 µg/mL), (23A- 3 µg/mL; 23B- 6 µg/mL), (25A- 2 µg/mL; 25B- 4 µg/mL) and (5A- 3 µg/mL; 5B- 6 µg/mL). Triplicates of each treatment group were used in each independent experiment. The statistical significance is expressed as * p < 0.05.